1. Home
  2. ACAD vs FTDR Comparison

ACAD vs FTDR Comparison

Compare ACAD & FTDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.41

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Frontdoor Inc.

FTDR

Frontdoor Inc.

HOLD

Current Price

$66.90

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACAD
FTDR
Founded
1993
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.4B
IPO Year
2000
2019

Fundamental Metrics

Financial Performance
Metric
ACAD
FTDR
Price
$21.41
$66.90
Analyst Decision
Buy
Buy
Analyst Count
22
5
Target Price
$30.55
$67.20
AVG Volume (30 Days)
1.2M
404.5K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
69.12
13.62
EPS
0.02
0.57
Revenue
$726,437,000.00
$2,093,000,000.00
Revenue This Year
$18.80
$5.97
Revenue Next Year
$11.70
$5.82
P/E Ratio
$1,092.00
$115.56
Revenue Growth
40.45
13.56
52 Week Low
$19.69
$48.47
52 Week High
$28.35
$70.77

Technical Indicators

Market Signals
Indicator
ACAD
FTDR
Relative Strength Index (RSI) 47.59 63.69
Support Level $21.04 $65.00
Resistance Level $22.03 $69.83
Average True Range (ATR) 0.60 1.71
MACD 0.06 0.41
Stochastic Oscillator 55.62 92.51

Price Performance

Historical Comparison
ACAD
FTDR

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About FTDR Frontdoor Inc.

Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.

Share on Social Networks: